Affordable Access

deepdyve-link
Publisher Website

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

Authors
  • Betts, Robert F
  • Nucci, Marcio
  • Talwar, Deepak
  • Gareca, Marcelo
  • Queiroz-Telles, Flavio
  • Bedimo, Roger J
  • Herbrecht, Raoul
  • Ruiz-Palacios, Guillermo
  • Young, Jo-Anne H
  • Baddley, John W
  • Strohmaier, Kim M
  • Tucker, Kimberly A
  • Taylor, Arlene F
  • Kartsonis, Nicholas A
Type
Published Article
Journal
Clinical Infectious Diseases
Publisher
Oxford University Press
Publication Date
Jun 15, 2009
Volume
48
Issue
12
Pages
1676–1684
Identifiers
DOI: 10.1086/598933
PMID: 19419331
Source
Medline
License
Unknown

Abstract

Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.

Report this publication

Statistics

Seen <100 times